FDA, EMEA To Hold Joint Scientific Advice Meetings With Sponsors
This article was originally published in The Pink Sheet Daily
Executive Summary
One-year pilot program will launch in January to address specific development issues for breakthrough products. Meetings will provide an "opportunity to optimize product development" and are expected to help avoid unnecessary replication or divergence in agency methodologies, FDA and EMEA say.
You may also be interested in...
EMEA Projects Drug Applications Will Double In 2006
Agency is unclear why applications are up, but notes that, unlike last year, there have been generic and biosimiliar applications.
EMEA Projects Drug Applications Will Double In 2006
Agency is unclear why applications are up, but notes that, unlike last year, there have been generic and biosimiliar applications.
Biogen Idec Assumes Aviptadil Development Responsibility From Mondobiotech
Phase III product would join a growing pulmonary arterial hypertension market.